Sales Reflect Sustained Growth, Particularly in Oncology and Vaccines
Total Worldwide Sales Were $16.0 Billion, an Increase of 7% From Third Quarter 2022; Excluding LAGEVRIO, Growth Was 6%;.
Merck Reveals Positive Results From Phase 3 KEYTRUDA Trials In Various Cancers finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
Evorpacept is the first CD47 blocker to show activity in a global randomized study in solid tumors Interim efficacy results showed the confirmed overall response rate for evorpacept.